WHO Use of Glucagon-Like Peptide-1 (GLP-1) Medications to Treat Obesity in Adults Guideline Patient Summary - Guideline Central
Objective
Overview
Diagnosis and Management

Use of Glucagon-Like Peptide-1 (GLP-1) Medications to Treat Obesity in Adults

World Health Organization


Publication Date: December 16, 2025

Source Citation

Celletti, Francesca et al. “World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults.” JAMA, 10.1001/jama.2025.24288. 1 Dec. 2025, doi:10.1001/jama.2025.24288

Disclaimer

The information in this patient summary should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.

You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.